Legend Biotech Corporation (LEGN) fair value analysis
Nasdaq · Updated 2026-10-19
LEGN price how computed
Valuation status
Awaiting full valuationLEGN's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once LEGN's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $18.48
- Sector
- Healthcare
- 12-month range
- $16.65–$36.28
- Market cap
- $3.59B
- From 52-week high
- -49.1%
- Shares outstanding
- 194M
- Rank in Healthcare by quality score
- #85 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Legend Biotech Corporation is a biopharmaceutical company that develops and commercializes cell therapies, primarily focusing on chimeric antigen receptor T cell therapies for cancer treatment. The company operates in multiple geographic regions including the United States, China, and other international markets.
LEGN currently ranks #85 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $3.59B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $1.27B
- Net margin
- -7.2%
- EPS (TTM)
- $-0.44
- Gross margin
- 64.5%
- Debt / equity
- 0.23
- Revenue growth (3-yr avg)
- 101.2%
- Shares outstanding
- 194M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 53 · neutral
- 50-day average
- $19.71
- 200-day average
- $22.24
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-11
- Last 8 quarters vs consensus
- 2 beat, 6 missed
- Quarter by quarter
- 2026-06 ▼ miss (-25.0%)
2026-03 ▼ miss (-1113.5%)
2025-12 ▲ beat (+15.8%)
2025-09 ▼ miss (-22.2%)
2025-06 ▼ miss (-195.7%)
2025-03 ▼ miss (-58.8%)
2024-12 ▲ beat (+137.2%)
2024-09 ▼ miss (-13.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 5 hold · 0 sell (13 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $45.6
- Target vs last price
- +146.8%
What our data shows for LEGN
- Shares are trading in the lower third of their 12-month price range of $16.65–$36.28.
- The 14-day relative strength index sits at a neutral 53.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- LEGN's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent LEGN news
TickrTrends' derived news-sentiment signal for LEGN is currently leaning positive, computed from recent coverage.
- Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy (manilatimes.net, 2026-10-15)
- Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma (manilatimes.net, 2026-10-01)
- LEGN Looks 76.4% Undervalued on GF Value™ Despite Unprofitable Status (gurufocus.com, 2026-09-25)
More LEGN news
- Can Legend Biotech (LEGN) Turn Cell Therapy Scale Into Compounding Wealth? (insidermonkey.com, 2026-09-25)
What people are saying
Follow the LEGN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for LEGN show a shift toward weaker momentum this week. The 50/200-day trend state moved from mixed to downtrend, while the RSI zone improved from oversold to neutral territory. The stock's valuation verdict remains awaiting full valuation.
- 2026-09-21 — TickrTrends' derived indicators for LEGN showed shifts this week across multiple metrics. The 50/200-day trend state moved from downtrend to mixed, while the RSI zone declined from neutral to oversold. The current valuation verdict remains awaiting full valuation.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is LEGN stock undervalued?
LEGN's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is LEGN's TickrTrends verdict?
LEGN is currently marked 'Awaiting full valuation' - a verdict publishes automatically once LEGN's own trailing P/E history validates under our standards.
How does LEGN compare to other Healthcare stocks?
LEGN ranks #85 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is LEGN overbought or oversold?
LEGN's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does LEGN report earnings next?
LEGN's next earnings report is scheduled for 2026-11-11, per the published earnings calendar.
Does LEGN usually beat earnings estimates?
Over its last 8 reported quarters LEGN beat the consensus estimate 2 times and missed 6 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about LEGN?
Of 13 analysts covering LEGN, 8 rate it a buy, 5 a hold and 0 a sell - buy-leaning, with a consensus price target of $45.6 (+146.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.